Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM) announced that CEO John Evans will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 5:15 p.m. PT in San Francisco.
The presentation will be available via a live webcast on the company's investor website at www.beamtx.com and the webcast will be archived for 60 days after the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – BEAM
On the day this news was published, BEAM gained 1.53%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: GLPG +1.61%, OCUL -4.39%, IDYA +0.09%, TARS -0.83%, TVTX -5.18%, suggesting BEAM’s -4.33% move is more stock-specific than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Investor conference | Neutral | -2.7% | Participation in Jefferies London Healthcare Conference with webcast access. |
| Nov 03 | Clinical data update | Positive | -3.0% | Updated BEACON Phase 1/2 BEAM-101 safety and efficacy data at ASH. |
| Aug 25 | Multiple conferences | Neutral | -1.2% | Planned participation in three major September 2025 investor conferences. |
| Aug 14 | Regulatory designation | Positive | +0.6% | FDA RMAT designation for BEAM-101 in sickle cell disease with promising trial data. |
| Aug 05 | Earnings and pipeline | Positive | -2.2% | Q2 2025 results and BEAM-302/BEAM-101 development updates with strong cash position. |
Recent news, including conferences and clinical updates, has often been followed by modest negative price reactions, even on seemingly positive developments.
Over the past few months, Beam has steadily communicated clinical, regulatory, and investor-relations milestones. In August 2025, it reported Q2 results with $1.2 billion in cash and progress across BEAM-302 and BEAM-101. Shortly after, BEAM-101 received FDA RMAT designation, and the BEACON Phase 1/2 trial reached 30 patients treated. Subsequent updates focused on additional data presentations and multiple investor conferences. Today’s J.P. Morgan conference appearance fits this pattern of ongoing investor outreach rather than a discrete clinical or financial catalyst.
Market Pulse Summary
This announcement highlights Beam’s participation in the high-profile J.P. Morgan Healthcare Conference, with a presentation on January 13, 2026 at 5:15 p.m. PT and a webcast archived for 60 days. It extends a recent pattern of investor-focused events following clinical advances and regulatory designations. Investors may watch for any new strategic, clinical, or partnership commentary during the talk, given Beam’s existing programs and previously disclosed cash position and development plans.
Key Terms
base editing medical
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, at 5:15 p.m. PT in San Francisco.
The live webcast will be available in the investor section of the company's website at www.beamtx.com and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contact:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
FAQ
When will Beam Therapeutics (BEAM) present at the J.P. Morgan Healthcare Conference?
Who from Beam Therapeutics (BEAM) is presenting at the conference?
How can investors watch Beam Therapeutics (BEAM) presentation on January 13, 2026?
Will the Beam Therapeutics (BEAM) webcast be available after the live presentation?
What is the event where Beam Therapeutics (BEAM) will present on January 13, 2026?
Is there a scheduled time and location for Beam's presentation at J.P. Morgan 2026?
